

# Non-Parametric Estimation of Optimal Individualized Treatment Rules for Survival Data

Andre Ehrlich

Athens University of Economics & Business

September 3, 2024

# Outline

- 1 Introduction
- 2 Survival Analysis
- 3 Direct Value Search
- 4 Outcome Weighted Learning
- 5 Application to Clinical Trial Data
- 6 Conclusion

# Outline

- 1 Introduction
- 2 Survival Analysis
- 3 Direct Value Search
- 4 Outcome Weighted Learning
- 5 Application to Clinical Trial Data
- 6 Conclusion

**Aim:** Introduction to Precision Medicine. Motivate non-parametric estimation approach.

**Aim:** Build understanding towards Bakoyannis (2023) "Estimating optimal individualized treatment rules with multistate processes", Biometrics.

**Keywords:** Precision Medicine , Individualised Treatment Rules, Dynamic Treatment Regimes

# Individualized Treatment Rules (ITRs)

- Identify subgroups of patients that respond differently to treatment
- Extend population health outcomes
- Spare patients from aggressive treatment if unlikely to benefit

# Individualized Treatment Rules (ITRs)




Figure: Point Exposure Prescriptive Treatment Effect

# Individualized Treatment Rules (ITRs)

An Individualized Treatment Rule recommends treatment  $A_i$  to patient  $i$  given their medical characteristics  $X$ .

$$ITR := f : X \rightarrow A$$

Goal: Learn optimal ITR function that optimise expected patient outcomes  $E[Y]$

# Desired ITR Properties

- ① Unbiased despite censored survival outcomes
- ② Operate under the Causal Inference framework
- ③ Guaranteed Convergence in finite sample
- ④ Robust to model misspecification (non-parametric)



# Simplest Problem Setup

- Randomized Controlled Trial (RCT) data
- Single treatment assignment stage ( $t=0$ )
- Binary treatment options:  $A \in \{-1, 1\}$




Figure: Single Stage, Two Arm

# Causal Inference Framework

- Observed Outcome

$$Y_i(A = a) \quad (1)$$

- Potential Outcomes:

$$Y_i^*(A = a), Y_i^*(A \neq a) \quad (2)$$

- Individual Treatment Effect:

$$\delta_i^* = Y_i^*(1) - Y_i^*(0) \quad (3)$$

- Average Treatment Effect:

$$\begin{aligned} \delta^* &= E[Y^*(1) - Y^*(0)] \\ &= n^{-1} \sum_1^n \left[ Y_i^*(A = 1) - Y_i^*(A = 0) \right] \end{aligned}$$

- **Aim:** Estimate Average Treatment Effect:

$$\delta^* = n^{-1} \sum_1^n \left[ Y_i^*(A = 1) - Y_i^*(A = 0) \right]$$

- For each patient, we can only ever observe one outcome!
- Missing Data estimation methods are useful here

# Causal Inference Assumptions

## ① **SUTVA: Stable Unit Treatment Value Assumption.**

- i) Patients do not affect each other.
- ii) Potential Outcome is equivalent to Observed.

$$Y_i = Y_i^*(1)A_i + Y_i^*(0)(1 - A_i), i = 1, \dots, n \quad (4)$$

## ② **Strong Ignorability:** No unmeasured confounders

$$\{Y^*(1), Y^*(0)\} \perp\!\!\!\perp A, X \quad (5)$$

## ③ **Positivity:** Non-zero probabilities of each treatment being assigned to each patient

$$P(A = a|X = x) > 0, a = 0, 1 \forall x \in X \text{ s.t. } P(X = x) > 0 \quad (6)$$

# Outcome Regression for Causal Inference

$$E[Y|A, X] = \beta_1 + \beta_2 a + \beta_3^T x + \beta_4^T xa + ||\lambda I|| \quad (7)$$

$$V_Q(d^*) = E\left\{\max_{a \in \mathbb{A}} Q(X, a; \beta)\right\} \quad (8)$$

Model Assumptions:

- ① **Linearity:** The relationship between  $X$  and the mean of  $Y$  is linear.
- ② **Homoscedasticity:** The variance of residual is the same for any value of  $X$ .
- ③ **Independence:** Observations are independent of each other.
- ④ **Normality:** For any fixed value of  $X$ ,  $Y$  is normally distributed.

# Inverse Probability Weighting (IPW)

Non-parametric M-estimator,  $\sqrt{N}$  consistent asymptotically normal

$$E[Y] = n^{-1} \sum_{i=1}^n Y \frac{A_i}{\pi(A_i|X_i)^{-1}} \quad (9)$$

Bias correction:

- 1 Causal Inference: Propensity of Treatment

$$w_A = \frac{I(D(X) = A)}{\pi(A|X)} \quad (10)$$

- 2 Survival Analysis: Probability of Censoring

$$w_C = \frac{I(C > \min(T, \tau))}{\pi(C|X)} \quad (11)$$

# IPW toy example

Observed population: aaaaaaaaaa bb

Calculate Weights:

$$p(a) = .8 \Rightarrow w_{ipw}(a) = 1.25$$

$$p(\text{not } a) = 0.2 \Rightarrow w_{ipw}(\text{not } a) = 5$$

Pseudo-population: aaaaaaaaaa**aa** bb**bbbbbbbbb**

Legend:

- Black = observed units
- Blue = pseudo-units

## Law of Total Expectation

$$E[X] = E[E[X|Y]]$$

- Double expectation over conditional expectation
- Can provide consistent estimates despite incomplete data

## Radon-Nikodym Derivative for IPW

$$\frac{dP_d}{dP_\pi} = \frac{I(a = D(x))}{P(A = a)}$$

- Change of Probability Measure
- Relies on Positivity Assumption



# Outline

- 1 Introduction
- 2 Survival Analysis**
- 3 Direct Value Search
- 4 Outcome Weighted Learning
- 5 Application to Clinical Trial Data
- 6 Conclusion

# Survival Data




Figure: Right-Censored Survival Data

# Survival Variables


$\tau$	End of Study
$T \in [0, +\infty]$	Survival Time
$C \in [0, +\infty]$	Censoring Time
$\tilde{T} = \min(T_i, \tau)$	Restricted Survival Time
$T^* = \min(\tilde{T}_i, C_i)$	Observed Restricted Survival Time
$\Delta_i = \mathbb{I}(\tilde{T}_i \leq C_i)$	Event Status

# Restricted Mean Survival Time (RMST)

$$E_{\tau}[Y(t)] = \int_0^{\tau} Y(t) dt \quad (12)$$


- Popular estimand in biomedical applications
- Avoids difficult extrapolation beyond end-of-study
- Interpretation: Which treatment yields higher probability of surviving at least 5-years?

# Restricted Survival - Scenario 1




# Restricted Survival - Scenario 2

② Censored  $\Delta = 0$



# Restricted Survival - Scenario 3



$$E[T] = n^{-1} \sum_{i=1}^n \frac{\Delta_i T_i}{P(C_i|X_i)} \quad (13)$$

- Corrects bias from right-censored observations
- Inflates observed survivals by inverse censoring probability



$$S(t) = P(T \geq t) = 1 - F(T \leq t) \quad (14)$$

Characterizes the probability that patient will survive up to or past time  $t$ .

# Hazard Function

- Instantaneous risk of death at time  $t$ , conditioned on survival up to time  $t$ .

$$\begin{aligned} h(t) &= \lim_{\epsilon \rightarrow 0} \frac{Pr(t < t + \epsilon | T \geq t)}{\epsilon} \\ &= f(t)/S(t) \\ &= \frac{-d \log S(t)}{dt} \end{aligned} \tag{15}$$

- Mathematically transportable to Survival Function

$$S(t) = \exp(-H(t)) \tag{16}$$

$$\hat{S}(t) \approx \prod_{i:t_i \leq t} \left(1 - \frac{d_i}{n_i}\right) \quad (17)$$

- Product-limit estimator naturally handles right-censored data
- Non-parametric estimator of survival function

# Cox Proportional Hazards Regression

$$\hat{h}(t; z) = h_0(t)\psi(t) \quad (18)$$

$$\psi(t) = \exp(z^T \beta), \beta \in \mathbb{R}^P \quad (19)$$

- Semi-parametric: Baseline hazard  $h_0$  left unspecified
- Parameterize only proportional hazard term  $\psi$
- Assumption: Hazard rates are proportional between groups over time

# Generating Survival Times from Cox Regression

## Inverse Transform Sampling

Uniformly-randomly distributed values  $U \sim U[0, 1]$  are plugged into the inverse CDF  $F^{-1}$  to sample from the distribution function.

$$S(t|x) = 1 - F(t)$$

$$= \exp(-H(t))$$

$$F(t) = U \sim \text{Unif}(0, 1)$$

$$U = 1 - S(t|x)$$

$$= S(t|x)$$

$$t = S^{-1}(U)$$

Survival Function

by defn Eq. 16

$$\text{Unif}(0, 1) = 1 - \text{Unif}(0, 1)$$

# Outline

- 1 Introduction
- 2 Survival Analysis
- 3 Direct Value Search**
- 4 Outcome Weighted Learning
- 5 Application to Clinical Trial Data
- 6 Conclusion

# Value Function

- The Value  $V(d)$  of a rule  $D(X) = d$  is the mean health outcome  $E[Y]$  on population  $X$
- Empirically select patients from sample that coincide with treatment of proposed rule  $D(X)$ , i.e.  $I(A = D(X))$

$$\begin{aligned} V(D) &= E_D(Y) \\ &= \int Y dP_D \\ &= \int Y \frac{dP_D}{dP} dP \\ &= E \left[ \frac{I(A = D(X))}{A\pi + (1 - A)/2} Y \right] \end{aligned} \tag{20}$$

# Direct Value Search Approach

- Treat ITR estimation as non-parametric classification problem
- Discover optimal treatment rule  $D^*$  that maximizes expected value  $E_D(Y)$

$$D^* \in \arg \max_{\mathcal{D}} E^D(Y) \quad (21)$$

- Equivalent to Empirical Risk Minimization (ERM)

$$D^* \in \arg \min_{\mathcal{D}} \mathcal{R}(D) \quad (22)$$



# Outline

- 1 Introduction
- 2 Survival Analysis
- 3 Direct Value Search
- 4 Outcome Weighted Learning**
- 5 Application to Clinical Trial Data
- 6 Conclusion

# Outcome Weighted Learning (OWL)

Zhao et al. (2012) propose using an IPW value estimator as criterion for Support Vector Machine (SVM) statistical learning algorithm

Value Function:

$$\mathcal{D}^* \in \arg \max_{\mathcal{D}} \mathbb{E} \left[ \frac{\mathbb{I}(A = \mathcal{D}(X))}{A\pi + (1 - A)/2} Y \right] \quad (23)$$

Specificity risk criterion to (any) classifier within the ERM framework.

$$\mathcal{R} = E \left[ \frac{I(A = D(X))}{A\pi + (1 - A)/2} \phi(Af(x)) \right] \quad (24)$$

Where  $\phi$  is a surrogate loss function (e.g., hinge loss for SVM).

# Support Vector Machine (SVM)

$$\left[ \frac{1}{n} \sum_{i=1}^n \phi \left( y_i (w^T x - b) \right) \right] + \lambda |w|^2 \quad (25)$$

- Statistical Learning methodology for classification
- Discriminatory hyperplane between two convex classes
- Soft-margin allows for optimisation over non-separable data
- Finite sample convergence for linear rules

# Hinge Loss

- Hinge loss is surrogate for 0-1 loss
- $\phi(x) = \max(0, 1 - x)$




Figure: SVM Hinge Loss Function

# SVM Covariance Structure

- Defined on Reproducing Hilbert Function Spaces (RHFS)
- Geometric dot-product spaces with defined covariance structure
- Focus on simple kernels:


Euclidean:  $K = X^T * X$

Gaussian:  $K(x_i, x_j) = -\gamma \|x_i - x_j\|^2$

$$\lim_{n \rightarrow \infty} \mathbb{P}\left(d(\tilde{f}_n, f^*) > \epsilon\right) \rightarrow 0, \forall \epsilon > 0 \quad (26)$$

- Weak convergence to tight mean gaussian limiting distribution.
- When restricted to the linear class of functions, ERM classifiers have guaranteed rate of weak convergence of  $n^{-1/2}$  (Tsybakov, 2004).
- Larger the dimensionality of covariate-space the slower the convergence of the estimator, large-P *curse of dimensionality*.
- Equicontinuity assumption states that at least one continuous covariate must be involved in order to ensure
- SVM rate of convergence depends partially on separability of the given data set and the number of support points lying along the separating margin. Zhao et al. (2012)
- Regularization Parameter  $\lambda$  plays role in convergence

# Optimal Linear Rule



**Figure:** Optimal linear rule  $\tilde{d}$  is a projection of true optimal rule  $d^*$  onto linear subspace.


# Inverse Censoring Outcome (ICO) Method

$$V(D) = \mathbb{E} \left[ \frac{\Delta_i}{\hat{S}_c(Y|A, X)} \frac{\mathbb{I}(A = \mathcal{D}(X))}{\pi(A; X)} T_i \right]$$

- Zhao et al. (2015) Extends OWL to handle right-censored data
- Compensates by Inverse Probability of Censoring weighting
- Assumes non-informative censoring
- Ignores censored outcomes  $\Rightarrow$  high variance



# SVM Visualisation



**Figure: Weighted SVM treatment classifier for right-censored data.**  
Number: Missclassification cost. Border: Solid=Uncensored, Dashed=Censored.  
Color: True Optimal Treatment

# Multistate Outcome Weighted Learning (MSOWL)

$$V(D) = \mathbb{E} \left( \left[ \int_0^\tau \frac{Y(t)I(C \geq (T_i \wedge t))}{S_c(\tilde{T} \wedge t)} dm(t) \right] \frac{\mathbb{I}(A_i = \mathcal{D}(X))}{\pi(A; X)} \right)$$

- Incorporates patient preferences of disease state & progression
- Fisher-consistent (lowest possible variance)
- Integrates each individual's multi-state stochastic process, even if censored, then take expectation
- Inverse Probability of Censoring Weighting on each Reimmanian rectangle discretized according to Kaplan-Meier event timepoints




Figure: MSOWL IPCW-Inflated Stochastic Integration

# Outline

- 1 Introduction
- 2 Survival Analysis
- 3 Direct Value Search
- 4 Outcome Weighted Learning
- 5 Application to Clinical Trial Data**
- 6 Conclusion

# Case Study with Real RCT Data

- "PRIME Trial"
- Disease: Pancreatic Cancer
- Treatments: Panitumumab (immuno) vs FOLFOX (chemo)
- Focus on Progression-Free Survival
- Clinical Markers: Age, ECOG, Sex
- Genetic Biomarker: KRAS (352 Mutant / 514 Wild-Type)
- Immunotherapy vs Chemotherapy: may reveal a delayed-response in survival curve, may invalidate Cox's proportional hazard assumption

# PRIME: Survival Curves




Figure: PRIME: Progression Free Survival (PFS)

# ITR Comparison Results

Estimator	$\hat{V}$	SE	ll	ul
ICO	11.10	0.40	10.20	11.90
MSOWL	12.20	0.6	11.00	13.40
COX	12.40	0.50	11.40	13.40
+1	11.40	0.40	10.60	12.30
-1	11.10	0.40	10.20	11.90

Table: PRIME PFS: ITR Value Comparison (Months)

- MSOWL outperforms the One-Size-Fits-All & ICO estimators
- MSOWL & Cox yield similar values

MSOWL Estimated Optimal Individualized Treatment Rule:

$$\hat{f}_{MSOWL} = 0.02 - 3.5e^{-8}X_{AGE} + 0.73X_{SEX} + 0.21X_{ECOG} - 1.06X_{KRAS}$$

- Sex, Ecog, and KRAS have significant effect on ITR recommendation



# Outline

- 1 Introduction
- 2 Survival Analysis
- 3 Direct Value Search
- 4 Outcome Weighted Learning
- 5 Application to Clinical Trial Data
- 6 Conclusion**

- OWL methods show promise for estimating ITRs with survival outcomes
- MSOWL offers improved efficiency, especially with censored data
- Tradeoffs between model flexibility and interpretability
- Importance of considering patient preferences and disease progression

- Find real data sets that exhibit OWL robustness w.r.t Regression
- Study effective sample size via simulation study
- Further investigation of non-linear treatment effects
- Further optimise SVM by formally explicitly minimizing aggressive treatment
- Integration of adverse event data into ITR estimation
- Extension to multiple treatment time points

- Bakoyannis, G. (2023). Estimating optimal individualized treatment rules with multistate processes. *Biometrics*.
- Tsybakov, A. B. (2004). Optimal aggregation of classifiers in statistical learning. *The Annals of Statistics*, 32(1):135–166.
- Zhao, Y., Zeng, D., Rush, A. J., and Kosorok, M. R. (2012). Estimating individualized treatment rules using outcome weighted learning. *Journal of the American Statistical Association*, 107(499):1106–1118.
- Zhao, Y. Q., Zeng, D., Laber, E. B., Song, R., Yuan, M., and Kosorok, M. R. (2015). Doubly robust learning for estimating individualized treatment with censored data. *Biometrika*, 102(1):151–168.